GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in Pancreatic Cancer

Stopped Preliminary data showed no survival benefit in the GV1001 group compared to the gemcitabine group.

Conditions

• Advanced Unresectable Pancreatic Cancer

Interventions

• BIOLOGICAL: GV1001
• DRUG: Gemcitabine (Chemotherapy)

Sponsor

Pharmexa A/S

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]